

## Anti-Human IgG (gamma chain) (Fluorescein Conjugated) Secondary Antibody

Goat Polyclonal, Fluorescein (FITC) Catalog # ASR2175

## **Product Information**

**Description** Anti-HUMAN IgG (gamma chain) (GOAT) Antibody Fluorescein Conjugated

**Host** Goat

Conjugate Fluorescein (FITC)

Target SpeciesHumanClonalityPolyclonalPhysical StateLyophilized

Host Isotype IgG

Target Isotype IgG (gamma chain)

**Buffer** 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Immunogen Human IgG gamma heavy chain

Reconstitution Volume 1.0 mL

**Reconstitution Buffer** Restore with deionized water (or equivalent)

## **Additional Information**

Shipping Condition Ambient

**Purity** This product was prepared from monospecific antiserum by immunoaffinity

chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Fluorescein, anti-Goat Serum, Human IgG and Human Serum. No reaction was observed against Human IgA or Human IgM. Specificity was confirmed by ELISA minimal cross reactivity against other Human heavy or

light chain isotypes.

**Storage Condition** Store vial at 4° C prior to restoration. For extended storage aliquot

contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted

liquid. Dilute only prior to immediate use.

**Precautions Note**This product is for research use only and is not intended for therapeutic or

diagnostic applications.

## Background

This product is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.